Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Recruiting
Observational Study
Metastatic Urothelial Carcinoma
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The obj…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients over 18 years of age
* Metastatic urothelial carcinoma
* Treated with first-line metastatic therapy since October 2024
Exclusion Criteria:
* Patient who expressed opposition to participating in the study
Contacts